Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity.
Fougeroux C, Goksøyr L, Idorn M, Soroka V, Myeni SK, Dagil R, Janitzek CM, Søgaard M, Aves KL, Horsted EW, Erdoğan SM, Gustavsson T, Dorosz J, Clemmensen S, Fredsgaard L, Thrane S, Vidal-Calvo EE, Khalifé P, Hulen TM, Choudhary S, Theisen M, Singh SK, Garcia-Senosiain A, Van Oosten L, Pijlman G, Hierzberger B, Domeyer T, Nalewajek BW, Strøbæk A, Skrzypczak M, Andersson LF, Buus S, Buus AS, Christensen JP, Dalebout TJ, Iversen K, Harritshøj LH, Mordmüller B, Ullum H, Reinert LS, de Jongh WA, Kikkert M, Paludan SR, Theander TG, Nielsen MA, Salanti A, Sander AF. Fougeroux C, et al. Nat Commun. 2021 Jan 12;12(1):324. doi: 10.1038/s41467-020-20251-8. Nat Commun. 2021. PMID: 33436573 Free PMC article.
Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants.
van Oosten L, Altenburg JJ, Fougeroux C, Geertsema C, van den End F, Evers WAC, Westphal AH, Lindhoud S, van den Berg W, Swarts DC, Deurhof L, Suhrbier A, Le TT, Torres Morales S, Myeni SK, Kikkert M, Sander AF, de Jongh WA, Dagil R, Nielsen MA, Salanti A, Søgaard M, Keijzer TMP, Weijers D, Eppink MHM, Wijffels RH, van Oers MM, Martens DE, Pijlman GP. van Oosten L, et al. Among authors: fougeroux c. mBio. 2021 Oct 26;12(5):e0181321. doi: 10.1128/mBio.01813-21. Epub 2021 Oct 12. mBio. 2021. PMID: 34634927 Free PMC article.
An S1-Nanoparticle Vaccine Protects against SARS-CoV-2 Challenge in K18-hACE2 Mice.
van Oosten L, Yan K, Rawle DJ, Le TT, Altenburg JJ, Fougeroux C, Goksøyr L, Adriaan de Jongh W, Nielsen MA, Sander AF, Pijlman GP, Suhrbier A. van Oosten L, et al. Among authors: fougeroux c. J Virol. 2022 Jul 27;96(14):e0084422. doi: 10.1128/jvi.00844-22. Epub 2022 Jun 29. J Virol. 2022. PMID: 35766489 Free PMC article. No abstract available.
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2.
Smit MJ, Sander AF, Ariaans MBPA, Fougeroux C, Heinzel C, Fendel R, Esen M, Kremsner PG, Ter Heine R, Wertheim HF, Idorn M, Paludan SR, Underwood AP, Binderup A, Ramirez S, Bukh J, Soegaard M, Erdogan SM, Gustavsson T, Clemmensen S, Theander TG, Salanti A, Hamborg M, de Jongh WA, McCall MBB, Nielsen MA, Mordmüller BG; COUGH-1 trial study group. Smit MJ, et al. Among authors: fougeroux c. Lancet Microbe. 2023 Mar;4(3):e140-e148. doi: 10.1016/S2666-5247(22)00337-8. Epub 2023 Jan 18. Lancet Microbe. 2023. PMID: 36681093 Free PMC article. Clinical Trial.
20 results